This site complies with the HONcode standard for trustworthy health information:
verify here
The FDA advisory panel which met to determine the safety of the diabetes drug Avandia has voted 20 – 12 to keep the drug on the market despite concerns over posiible cardiac risks. 10 members also recommended limiting who can prescribe the drug and who should be allowed to take it.
The FDA has promised to review the findings of the panel and make their decision as soon as possible. While they do not have to follow the recommendations of the advisory panels they usually do. bjmdjd
Material modifications since posting: none
Avandia · Food and Drug Administration
